title: The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease.
authors.affiliation: Divisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA Winthrop@ohsu.edu.
authors.forename: Kevin L
authors.initials: KL
authors.lastname: Winthrop
authors.affiliation: Divisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA.
authors.forename: Jennifer H
authors.initials: JH
authors.lastname: Ku
authors.affiliation: University of Toronto, Toronto, Canada.
authors.forename: Theodore K
authors.initials: TK
authors.lastname: Marras
authors.affiliation: University of Texas at Tyler, Tyler, TX, USA.
authors.forename: David E
authors.initials: DE
authors.lastname: Griffith
authors.affiliation: National Jewish Health, Denver, CO, USA.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Daley
authors.affiliation: National Institute Allergy and Infectious Diseases, Bethesda, MD, USA.
authors.forename: Kenneth N
authors.initials: KN
authors.lastname: Olivier
authors.affiliation: Mayo Clinic, Rochester, MN, USA.
authors.forename: Timothy R
authors.initials: TR
authors.lastname: Aksamit
authors.affiliation: Divisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA.
authors.forename: Cara D
authors.initials: CD
authors.lastname: Varley
authors.affiliation: Divisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA.
authors.forename: Katherine
authors.initials: K
authors.lastname: Mackey
authors.affiliation: National Institute Allergy and Infectious Diseases, Bethesda, MD, USA.
authors.forename: D Rebecca
authors.initials: DR
authors.lastname: Prevots
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D000069349:Linezolid / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis / Q000188:drug therapy*; D009170:Nontuberculous Mycobacteria / Q000187:drug effects* / Q000302:isolation & purification; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000069349:Linezolid